NovoCure Shares Fall After Narrower Q3 Loss, Revenue Beat

MT Newswires Live10-29 22:22

NovoCure (NVCR) shares fell 9.6% in early Thursday trading after the company reported a narrower Q3 loss and revenue that beat expectations.

The company reported a Q3 net loss Thursday of $0.09 per diluted share, narrowing from a loss of $0.33 a year earlier.

Analysts polled by FactSet expected a loss of $0.23.

Revenue for the quarter ended Sept. 30 was $193.4 million, up from $167.2 million a year earlier.

Analysts expected $182.3 million.

The company raised its 2026 revenue guidance to $736 million to $743 million from the prior guidance of $710 million to $725 million. Analysts expect $726.1 million.

Price: 12.81, Change: -1.36, Percent Change: -9.60

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment